MicroRNA-125b reduces glucose uptake in papillary thyroid carcinoma cells

Guowu Zhang1, Sihai Zhou1, Quan Yang2

  • 1Department of General Surgery, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, P.R. China.

Oncology Letters
|August 13, 2020
PubMed

Insights

MicroRNA (miR)-125b is downregulated in papillary thyroid carcinoma (PTC), impacting cancer progression. This study reveals miR-125b suppresses PTC cell proliferation and glucose uptake by targeting glucose transporter 1 (GLUT1).

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • MicroRNA (miR)-125b is implicated in various human cancers.
  • Its specific role in papillary thyroid carcinoma (PTC) requires further elucidation.

Purpose of the Study:

  • To investigate the function of miR-125b in papillary thyroid carcinoma (PTC).
  • To explore the relationship between miR-125b, glucose transporter 1 (GLUT1), and PTC progression.

Main Methods:

  • Analysis of miR-125b and GLUT1 expression in PTC tissues.
  • In vitro studies involving overexpression of miR-125b and GLUT1 in PTC cells.
  • Assessment of glucose uptake and cell proliferation rates.

Main Results:

  • miR-125b was found to be downregulated in PTC, with expression levels varying by clinical stage.
  • GLUT1 was upregulated in PTC and showed a negative correlation with miR-125b expression.
  • Overexpression of miR-125b in PTC cells led to suppressed glucose uptake and reduced GLUT1 levels.
  • miR-125b overexpression inhibited PTC cell proliferation, while GLUT1 overexpression promoted it.
  • GLUT1 partially reversed the effects of miR-125b on glucose uptake and proliferation.

Conclusions:

  • miR-125b acts as a tumor suppressor in PTC.
  • miR-125b decreases glucose uptake in PTC cells primarily by downregulating GLUT1.
  • The miR-125b/GLUT1 axis represents a potential therapeutic target for PTC.